New Stock News | Simai Pharmaceutical Submits Forms to Hong Kong Stock Exchange

According to JETCO Financial APP, as disclosed by the Hong Kong Stock Exchange on November 12, Zhejiang Shimai Pharmaceutical Co., Ltd.-B (hereinafter referred to as Shimai Pharmaceutical) has submitted an application to the Hong Kong Stock Exchange main board, with Huatai International as its exclusive sponsor. According to the prospectus, the company was established in 2017 and is a pioneer and global leader in the next generation T-cell engager (TCE) therapy. TCE is a bispecific or multispecific antibody that is designed to simultaneously bind to tumor-associated antigens (TAA) on tumor cells and receptors on T cells, targeting tumor tissues and activating T cells to induce targeted cytotoxicity. The company early on recognized the differentiated potential of TCE, which is a next-generation immune therapy aimed at utilizing and guiding the human immune system to fight cancer.